RUNX2 prompts triple negative breast cancer drug resistance through TGF-β pathway regulating breast cancer stem cells

RUNX2 prompts triple negative breast cancer drug resistance through TGF-β pathway regulating breast cancer stem cells

Triple-negative breast cancer (TNBC) stands out as the most aggressive subtype within the spectrum of breast cancer. The current clinical guidelines propose treatment strategies involving cytotoxic agents like epirubicin or paclitaxel. However, the emergence of acquired resistance frequently precipi...

Deskribapen osoa

Xehetasun bibliografikoak
Egile Nagusiak: Fengxu Lv, Wentao Si, Xiaodan Xu, Xiaogang He, Ying Wang, Yetian Li, Feifei Li
Formatua: Artikulua
Hizkuntza:English
Argitaratua: Elsevier 2024-02-01
Saila:Neoplasia: An International Journal for Oncology Research
Gaiak:
Triple negative breast cancer
Chemoresistance
Cancer stem cells
RUNX2
TGF-β
Sarrera elektronikoa:http://www.sciencedirect.com/science/article/pii/S1476558624000046

Internet

http://www.sciencedirect.com/science/article/pii/S1476558624000046

Antzeko izenburuak